Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development.

Beites T, O'Brien K, Tiwari D, Engelhart CA, Walters S, Andrews J, Yang HJ, Sutphen ML, Weiner DM, Dayao EK, Zimmerman M, Prideaux B, Desai PV, Masquelin T, Via LE, Dartois V, Boshoff HI, Barry CE 3rd, Ehrt S, Schnappinger D.

Nat Commun. 2019 Oct 31;10(1):4970. doi: 10.1038/s41467-019-12956-2.

2.

The Prevalence of Bladder Cancer During Cystoscopy for Asymptomatic Microscopic Hematuria.

Gonzalez AN, Lipsky MJ, Li G, Rutman MP, Cooper KL, Weiner DM, Badalato G, Decastro GJ, Wenske S, McKiernan JM, Anderson CB.

Urology. 2019 Apr;126:34-38. doi: 10.1016/j.urology.2019.01.011. Epub 2019 Jan 22.

PMID:
30677457
3.

A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.

Merchant KM, Cedarbaum JM, Brundin P, Dave KD, Eberling J, Espay AJ, Hutten SJ, Javidnia M, Luthman J, Maetzler W, Menalled L, Reimer AN, Stoessl AJ, Weiner DM; The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group.

J Parkinsons Dis. 2019;9(1):31-61. doi: 10.3233/JPD-181471.

4.

Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2'-Oxidase.

Oh S, Park Y, Engelhart CA, Wallach JB, Schnappinger D, Arora K, Manikkam M, Gac B, Wang H, Murgolo N, Olsen DB, Goodwin M, Sutphin M, Weiner DM, Via LE, Boshoff HIM, Barry CE 3rd.

J Med Chem. 2018 Nov 21;61(22):9952-9965. doi: 10.1021/acs.jmedchem.8b00883. Epub 2018 Nov 5.

5.

The association between sterilizing activity and drug distribution into tuberculosis lesions.

Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O'Brien P, Chen C, Kaya F, Weiner DM, Chen PY, Song T, Lee M, Shim TS, Cho JS, Kim W, Cho SN, Olivier KN, Barry CE 3rd, Dartois V.

Nat Med. 2015 Oct;21(10):1223-7. doi: 10.1038/nm.3937. Epub 2015 Sep 7.

6.

Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives.

Via LE, Savic R, Weiner DM, Zimmerman MD, Prideaux B, Irwin SM, Lyon E, O'Brien P, Gopal P, Eum S, Lee M, Lanoix JP, Dutta NK, Shim T, Cho JS, Kim W, Karakousis PC, Lenaerts A, Nuermberger E, Barry CE 3rd, Dartois V.

ACS Infect Dis. 2015 May 8;1(5):203-214.

7.

A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets.

Via LE, England K, Weiner DM, Schimel D, Zimmerman MD, Dayao E, Chen RY, Dodd LE, Richardson M, Robbins KK, Cai Y, Hammoud D, Herscovitch P, Dartois V, Flynn JL, Barry CE 3rd.

Antimicrob Agents Chemother. 2015 Jul;59(7):4181-9. doi: 10.1128/AAC.00115-15. Epub 2015 May 4.

8.

Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery.

Datta M, Via LE, Kamoun WS, Liu C, Chen W, Seano G, Weiner DM, Schimel D, England K, Martin JD, Gao X, Xu L, Barry CE 3rd, Jain RK.

Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1827-32. doi: 10.1073/pnas.1424563112. Epub 2015 Jan 26.

9.

Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus).

Via LE, Weiner DM, Schimel D, Lin PL, Dayao E, Tankersley SL, Cai Y, Coleman MT, Tomko J, Paripati P, Orandle M, Kastenmayer RJ, Tartakovsky M, Rosenthal A, Portevin D, Eum SY, Lahouar S, Gagneux S, Young DB, Flynn JL, Barry CE 3rd.

Infect Immun. 2013 Aug;81(8):2909-19. doi: 10.1128/IAI.00632-13. Epub 2013 May 28.

10.

Functional enhancement of AT1R potency in the presence of the TPαR is revealed by a comprehensive 7TM receptor co-expression screen.

Hansen JT, Lyngsø C, Speerschneider T, Hansen PB, Galés C, Weiner DM, Sheikh SP, Burstein ES, Hansen JL.

PLoS One. 2013;8(3):e58890. doi: 10.1371/journal.pone.0058890. Epub 2013 Mar 14.

11.

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.

Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U.

Schizophr Res. 2012 Nov;141(2-3):144-52. doi: 10.1016/j.schres.2012.07.029. Epub 2012 Sep 4.

12.

Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.

Via LE, Schimel D, Weiner DM, Dartois V, Dayao E, Cai Y, Yoon YS, Dreher MR, Kastenmayer RJ, Laymon CM, Carny JE, Flynn JL, Herscovitch P, Barry CE 3rd.

Antimicrob Agents Chemother. 2012 Aug;56(8):4391-402. doi: 10.1128/AAC.00531-12. Epub 2012 Jun 11.

13.

Striatal activity in borderline personality disorder with comorbid intermittent explosive disorder: sex differences.

Perez-Rodriguez MM, Hazlett EA, Rich EL, Ripoll LH, Weiner DM, Spence N, Goodman M, Koenigsberg HW, Siever LJ, New AS.

J Psychiatr Res. 2012 Jun;46(6):797-804. doi: 10.1016/j.jpsychires.2012.02.014. Epub 2012 Mar 29.

14.

Priorities in Parkinson's disease research.

Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E.

Nat Rev Drug Discov. 2011 May;10(5):377-93. doi: 10.1038/nrd3430. Review.

PMID:
21532567
15.

High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions.

Prideaux B, Dartois V, Staab D, Weiner DM, Goh A, Via LE, Barry CE 3rd, Stoeckli M.

Anal Chem. 2011 Mar 15;83(6):2112-8. doi: 10.1021/ac1029049. Epub 2011 Feb 18.

16.

Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers.

Ancoli-Israel S, Vanover KE, Weiner DM, Davis RE, van Kammen DP.

Sleep Med. 2011 Feb;12(2):134-41. doi: 10.1016/j.sleep.2010.10.004. Epub 2011 Jan 21.

17.

Lack of evidence for AT1R/B2R heterodimerization in COS-7, HEK293, and NIH3T3 cells: how common is the AT1R/B2R heterodimer?

Hansen JL, Hansen JT, Speerschneider T, Lyngsø C, Erikstrup N, Burstein ES, Weiner DM, Walther T, Makita N, Iiri T, Merten N, Kostenis E, Sheikh SP.

J Biol Chem. 2009 Jan 16;284(3):1831-9. doi: 10.1074/jbc.M804607200. Epub 2008 Nov 18.

18.

The human angiotensin AT(1) receptor supports G protein-independent extracellular signal-regulated kinase 1/2 activation and cellular proliferation.

Hansen JL, Aplin M, Hansen JT, Christensen GL, Bonde MM, Schneider M, Haunsø S, Schiffer HH, Burstein ES, Weiner DM, Sheikh SP.

Eur J Pharmacol. 2008 Aug 20;590(1-3):255-63. doi: 10.1016/j.ejphar.2008.05.010. Epub 2008 May 20.

PMID:
18565507
19.

A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.

Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD.

Pharmacol Biochem Behav. 2008 Oct;90(4):540-4. doi: 10.1016/j.pbb.2008.04.010.

20.

Constitutively active mutants of the histamine H1 receptor suggest a conserved hydrophobic asparagine-cage that constrains the activation of class A G protein-coupled receptors.

Bakker RA, Jongejan A, Sansuk K, Hacksell U, Timmerman H, Brann MR, Weiner DM, Pardo L, Leurs R.

Mol Pharmacol. 2008 Jan;73(1):94-103. Epub 2007 Oct 24.

PMID:
17959710
21.

PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.

Nordstrom AL, Mansson M, Jovanovic H, Karlsson P, Halldin C, Farde L, Vanover KE, Hacksell U, Brann MR, Davis RE, Weiner DM.

Int J Neuropsychopharmacol. 2008 Mar;11(2):163-71. Epub 2007 Aug 21.

PMID:
17708779
22.

Pharmacology of N-desmethylclozapine.

Lameh J, Burstein ES, Taylor E, Weiner DM, Vanover KE, Bonhaus DW.

Pharmacol Ther. 2007 Aug;115(2):223-31. Epub 2007 May 21. Review.

PMID:
17583355
23.

The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers.

Vanover KE, Robbins-Weilert D, Wilbraham DG, Mant TG, van Kammen DP, Davis RE, Weiner DM.

J Clin Pharmacol. 2007 Jul;47(7):915-9. Epub 2007 May 10. No abstract available.

PMID:
17495279
24.

Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers.

Vanover KE, Robbins-Weilert D, Wilbraham DG, Mant TG, van Kammen DP, Davis RE, Weiner DM.

J Clin Pharmacol. 2007 Jun;47(6):704-14. Epub 2007 May 1.

PMID:
17473118
25.

In vitro pharmacology of clinically used central nervous system-active drugs as inverse H(1) receptor agonists.

Bakker RA, Nicholas MW, Smith TT, Burstein ES, Hacksell U, Timmerman H, Leurs R, Brann MR, Weiner DM.

J Pharmacol Exp Ther. 2007 Jul;322(1):172-9. Epub 2007 Apr 2.

PMID:
17403993
26.

Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer.

Schiffer HH, Reding EC, Fuhs SR, Lu Q, Piu F, Wong S, Littler PL, Weiner DM, Keefe W, Tan PK, Nash NR, Knapp AE, Olsson R, Brann MR.

Mol Pharmacol. 2007 Feb;71(2):508-18. Epub 2006 Sep 12.

PMID:
16968809
27.

Integrative functional assays, chemical genomics and high throughput screening: harnessing signal transduction pathways to a common HTS readout.

Burstein ES, Piu F, Ma JN, Weissman JT, Currier EA, Nash NR, Weiner DM, Spalding TA, Schiffer HH, Del Tredici AL, Brann MR.

Curr Pharm Des. 2006;12(14):1717-29.

PMID:
16712484
28.

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.

Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE.

J Pharmacol Exp Ther. 2006 May;317(2):910-8. Epub 2006 Feb 9.

PMID:
16469866
29.

Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.

Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR.

J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. Epub 2005 Aug 31.

PMID:
16135699
30.

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.

Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, Hacksell U, Burstein ES, Davis RE, Brann MR.

Psychopharmacology (Berl). 2004 Dec;177(1-2):207-16. Epub 2004 Jul 16.

PMID:
15258717
31.

Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist.

Vanover KE, Harvey SC, Son T, Bradley SR, Kold H, Makhay M, Veinbergs I, Spalding TA, Weiner DM, Andersson CM, Tolf BR, Brann MR, Hacksell U, Davis RE.

J Pharmacol Exp Ther. 2004 Sep;310(3):943-51. Epub 2004 Apr 21.

PMID:
15102927
32.

Functional screening of drug target genes: m1 muscarinic acetylcholine receptor phenotypes in degenerative dementias.

Weiner DM, Goodman MW, Colpitts TM, Feddock MA, Duggento KL, Nash NR, Levey AI, Brann MR.

Am J Pharmacogenomics. 2004;4(2):119-28.

PMID:
15059034
33.

Pharmacology of polymorphic variants of the human 5-HT1A receptor.

Del Tredici AL, Schiffer HH, Burstein ES, Lameh J, Mohell N, Hacksell U, Brann MR, Weiner DM.

Biochem Pharmacol. 2004 Feb 1;67(3):479-90.

PMID:
15037200
34.

Loss-of-function polymorphic variants of the human angiotensin II type 1 receptor.

Hansen JL, Haunsø S, Brann MR, Sheikh SP, Weiner DM.

Mol Pharmacol. 2004 Mar;65(3):770-7.

PMID:
14978256
35.

8R-lisuride is a potent stereospecific histamine H1-receptor partial agonist.

Bakker RA, Weiner DM, ter Laak T, Beuming T, Zuiderveld OP, Edelbroek M, Hacksell U, Timmerman H, Brann MR, Leurs R.

Mol Pharmacol. 2004 Mar;65(3):538-49. Erratum in: Mol Pharmacol. 2004 Apr;65(4):1048.

PMID:
14978232
36.

Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics.

Weiner DM, Vanover KE, Brann MR, Meltzer HY, Davis RE.

Curr Opin Investig Drugs. 2003 Jul;4(7):815-9. Review.

PMID:
14619402
37.

RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms.

Marion S, Weiner DM, Caron MG.

J Biol Chem. 2004 Jan 23;279(4):2945-54. Epub 2003 Nov 5.

38.

Alfuzosin for the management of benign prostate hyperplasia.

Weiner DM, Lowe FC.

Expert Opin Pharmacother. 2003 Nov;4(11):2057-63. Review.

PMID:
14596659
39.

Distribution analysis of nonsynonymous polymorphisms within the G-protein-coupled receptor gene family.

Lee A, Rana BK, Schiffer HH, Schork NJ, Brann MR, Insel PA, Weiner DM.

Genomics. 2003 Mar;81(3):245-8.

PMID:
12659808
40.

Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H(3) receptor.

Wellendorph P, Goodman MW, Burstein ES, Nash NR, Brann MR, Weiner DM.

Neuropharmacology. 2002 Jun;42(7):929-40.

PMID:
12069903
41.

Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6.

Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL.

J Biol Chem. 2002 Mar 29;277(13):11441-9. Epub 2002 Jan 18. Erratum in: J Biol Chem 2002 May 17;277(20):18244.

42.

RNA editing of the human serotonin 5-HT2C receptor alters receptor-mediated activation of G13 protein.

Price RD, Weiner DM, Chang MS, Sanders-Bush E.

J Biol Chem. 2001 Nov 30;276(48):44663-8. Epub 2001 Sep 25.

43.

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.

Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DF, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR.

J Pharmacol Exp Ther. 2001 Oct;299(1):268-76.

PMID:
11561089
44.

Electrosurgery: VaporTrode.

Weiner DM, Kaplan SA.

Eur Urol. 1999 Feb;35(2):166-72. Review.

PMID:
9933811
45.

The tuberous sclerosis complex: a comprehensive review.

Weiner DM, Ewalt DH, Roach ES, Hensle TW.

J Am Coll Surg. 1998 Nov;187(5):548-61. Review. No abstract available.

PMID:
9809574
46.

Obstructive uropathy due to sliding inguinal hernia.

Saidi JA, Weiner DM, Puchner PJ.

Urology. 1998 Jun;51(6):1035-6. No abstract available.

PMID:
9609648
47.
48.
49.
50.

D1 and D2 dopamine receptor mRNA in rat brain.

Weiner DM, Levey AI, Sunahara RK, Niznik HB, O'Dowd BF, Seeman P, Brann MR.

Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1859-63.

Supplemental Content

Loading ...
Support Center